Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Monday, Zacks reports.

Other research analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Trading Up 0.2%

NASDAQ SUPN opened at $42.83 on Monday. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -22.31, a PEG ratio of 0.79 and a beta of 0.55. Supernus Pharmaceuticals has a 12 month low of $40.51 and a 12 month high of $59.68. The company’s 50 day moving average is $44.49 and its two-hundred day moving average is $46.83.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.Supernus Pharmaceuticals’s quarterly revenue was up 32.4% compared to the same quarter last year. During the same period last year, the firm posted $0.40 EPS. Sell-side analysts forecast that Supernus Pharmaceuticals will post 1.97 EPS for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at $434,871,000. Bank of America Corp DE acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $28,887,000. Assenagon Asset Management S.A. purchased a new position in Supernus Pharmaceuticals in the 1st quarter worth $27,428,000. Rice Hall James & Associates LLC purchased a new position in Supernus Pharmaceuticals in the 2nd quarter worth $22,800,000. Finally, Bank of New York Mellon Corp acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $17,553,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.